BlinkLab (ASX:BB1) entered into an academic research agreement with Erasmus University Medical Center in the Netherlands to investigate treatment-related changes in behavioral and neurodevelopmental function in patients with Activated PI3K Delta Syndrome, a rare disorder associated with neurodevelopmental and behavioral symptoms, including autism, according to a Tuesday Australian bourse filing.
The study evaluates behavioral and neurodevelopmental function before and during treatment with a selective PI3Kδ inhibitor, a pathway-targeted therapy in the syndrome.